167 related articles for article (PubMed ID: 23435431)
1. Myocyte enhancer factor 2C in hematopoiesis and leukemia.
Canté-Barrett K; Pieters R; Meijerink JP
Oncogene; 2014 Jan; 33(4):403-10. PubMed ID: 23435431
[TBL] [Abstract][Full Text] [Related]
2. MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus.
Canté-Barrett K; Meijer MT; Cordo' V; Hagelaar R; Yang W; Yu J; Smits WK; Nulle ME; Jansen JP; Pieters R; Yang JJ; Haigh JJ; Goossens S; Meijerink JP
JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35536646
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine phenotypes in a boy with 5q14 deletion syndrome implicate the regulatory roles of myocyte-specific enhancer factor 2C in the postnatal hypothalamus.
Sakai Y; Ohkubo K; Matsushita Y; Akamine S; Ishizaki Y; Torisu H; Ihara K; Sanefuji M; Kim MS; Lee KU; Shaw CA; Lim J; Nakabeppu Y; Hara T
Eur J Med Genet; 2013 Sep; 56(9):475-83. PubMed ID: 23832106
[TBL] [Abstract][Full Text] [Related]
4. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Kentsis A; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
J Hematol Oncol; 2015 Oct; 8():115. PubMed ID: 26487643
[TBL] [Abstract][Full Text] [Related]
5. Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors.
Zuurbier L; Gutierrez A; Mullighan CG; Canté-Barrett K; Gevaert AO; de Rooi J; Li Y; Smits WK; Buijs-Gladdines JG; Sonneveld E; Look AT; Horstmann M; Pieters R; Meijerink JP
Haematologica; 2014 Jan; 99(1):94-102. PubMed ID: 23975177
[TBL] [Abstract][Full Text] [Related]
6. Postnatal expression patterns and polymorphism analysis of the bovine myocyte enhancer factor 2C (Mef2C) gene.
Juszczuk-Kubiak E; Wicińska K; Starzyński RR
Meat Sci; 2014 Dec; 98(4):753-8. PubMed ID: 25108515
[TBL] [Abstract][Full Text] [Related]
7. Myocyte enhancer factor 2C and its directly-interacting proteins: A review.
Dong C; Yang XZ; Zhang CY; Liu YY; Zhou RB; Cheng QD; Yan EK; Yin DC
Prog Biophys Mol Biol; 2017 Jul; 126():22-30. PubMed ID: 28163053
[TBL] [Abstract][Full Text] [Related]
8. Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo.
Tarumoto Y; Lin S; Wang J; Milazzo JP; Xu Y; Lu B; Yang Z; Wei Y; Polyanskaya S; Wunderlich M; Gray NS; Stegmaier K; Vakoc CR
Blood; 2020 Jan; 135(1):56-70. PubMed ID: 31697837
[TBL] [Abstract][Full Text] [Related]
9. MEF2C and EBF1 Co-regulate B Cell-Specific Transcription.
Kong NR; Davis M; Chai L; Winoto A; Tjian R
PLoS Genet; 2016 Feb; 12(2):e1005845. PubMed ID: 26900922
[TBL] [Abstract][Full Text] [Related]
10. The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Barneda-Zahonero B; Collazo O; Azagra A; Fernández-Duran I; Serra-Musach J; Islam AB; Vega-García N; Malatesta R; Camós M; Gómez A; Román-González L; Vidal A; López-Bigas N; Villanueva A; Esteller M; Parra M
Cell Death Dis; 2015 Feb; 6(2):e1635. PubMed ID: 25675295
[TBL] [Abstract][Full Text] [Related]
11. MEF2C exon α: role in gene activation and differentiation.
Infantino V; Convertini P; Menga A; Iacobazzi V
Gene; 2013 Dec; 531(2):355-62. PubMed ID: 24008018
[TBL] [Abstract][Full Text] [Related]
12. Myocyte Enhancer Factor 2C as a New Player in Human Breast Cancer Brain Metastases.
Galego S; Kauppila LA; Malhó R; Pimentel J; Brito MA
Cells; 2021 Feb; 10(2):. PubMed ID: 33673112
[TBL] [Abstract][Full Text] [Related]
13. Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations.
Andersson A; Olofsson T; Lindgren D; Nilsson B; Ritz C; Edén P; Lassen C; Råde J; Fontes M; Mörse H; Heldrup J; Behrendtz M; Mitelman F; Höglund M; Johansson B; Fioretos T
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19069-74. PubMed ID: 16354839
[TBL] [Abstract][Full Text] [Related]
14. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
15. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
16. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow-induced Mef2c deficiency delays B-cell development and alters the expression of key B-cell regulatory proteins.
Debnath I; Roundy KM; Pioli PD; Weis JJ; Weis JH
Int Immunol; 2013 Feb; 25(2):99-115. PubMed ID: 23087187
[TBL] [Abstract][Full Text] [Related]
18. MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.
Colomer-Lahiguera S; Pisecker M; König M; Nebral K; Pickl WF; Kauer MO; Haas OA; Ullmann R; Attarbaschi A; Dworzak MN; Strehl S
Leuk Lymphoma; 2017 Dec; 58(12):2895-2904. PubMed ID: 28482719
[TBL] [Abstract][Full Text] [Related]
19. Mef2c is activated directly by Ets transcription factors through an evolutionarily conserved endothelial cell-specific enhancer.
De Val S; Anderson JP; Heidt AB; Khiem D; Xu SM; Black BL
Dev Biol; 2004 Nov; 275(2):424-34. PubMed ID: 15501228
[TBL] [Abstract][Full Text] [Related]
20. MEF2C promotes M1 macrophage polarization and Th1 responses.
Zhao X; Di Q; Liu H; Quan J; Ling J; Zhao Z; Xiao Y; Wu H; Wu Z; Song W; An H; Chen W
Cell Mol Immunol; 2022 Apr; 19(4):540-553. PubMed ID: 35194174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
